



Freedom of Information Team
De La Court House
Queen Alexandra Hospital
Southwick Hill Road
Portsmouth
Hampshire
PO6 3LY

Name:
Email:
Date: 26/07/2023
Ref: 23-24 215

Dear

RE: Freedom of Information request

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 05/07/2023. Please see responses to your requests below.

Q1. Does your trust treat myeloproliferative neoplasms? If not, which other trust do you refer these patients to?

Yes, Portsmouth Hospitals University NHS Trust does provide treatments for myeloproliferative neoplasms.

Q2. Please provide the total number of patients treated in the last 6 months for:

Please see table below. The data is taken from the latest complete SACT (systemic anti-cancer therapy) submission which is up to and including February 2023.

Treatment	Patients
Polycythaemia Vera (ICD10 code D45)	53
Myelofibrosis (ICD10 code D47.4)	21
Myelofibrosis (ICD10 code D47.4) patients aged 65 and older	19

Q3. How many patients were treated in the past 6 months (for any disease) with:

Please see table below. The data is taken from the latest complete SACT submission which is up to and including February 2023.

Treatment	Patients
Ruxolitinib	<5
Fedratinib	0

The Trust is unable to provide precise figures when these are less than five due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure.

Q4. Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for:

Please see table below. The data is taken from the latest complete SACT submission which is up to and including February 2023.

Diagnosis	Patients
Polycythaemia Vera (ICD10 code D45)	0
Myelofibrosis (ICD10 code D47.4)	<5

Please see exemption in question 3.

Q5. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

The commissioning dataset only captures activity, and we therefore cannot answer this question.

- **Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?**
- **Of these patients, how many were treated in the past 6 months with Interferon therapy?**
- **Of these patients, how many have received no active treatment in the past 6 months?**

The Trust is only able to provide information in relation to drug dispensing, we do not record diagnoses on our clinical systems so therefore we are unable to provide the information requested.

Q6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

Portsmouth Hospitals University NHS Trust is not participating in any clinical trials for the treatment of myelofibrosis.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on Information.Governance@porthosp.nhs.uk or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team